A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process.
A licensed pharmaceutical process is required to be executed within the validated ranges throughout the lifetime of product manufacturing. Changes to the process, especially for processes involving biological products, usually require the manufacturer to demonstrate that the safety and efficacy of the product remains unchanged by new or additional clinical testing. Recent changes in the regulations for pharmaceutical processing allow broader ranges of process settings to be submitted for regulatory approval, the so-called process design space, which means that a manufacturer can optimize his process within the submitted ranges after the product has entered the market, which allows flexible processes. In this article, the applicability of this concept of the process design space is investigated for the cultivation process step for a vaccine against whooping cough disease. An experimental design (DoE) is applied to investigate the ranges of critical process parameters that still result in a product that meets specifications. The on-line process data, including near infrared spectroscopy, are used to build a descriptive model of the processes used in the experimental design. Finally, the data of all processes are integrated in a multivariate batch monitoring model that represents the investigated process design space. This article demonstrates how the general principles of PAT and process design space can be applied for an undefined biological product such as a whole cell vaccine. The approach chosen for model development described here, allows on line monitoring and control of cultivation batches in order to assure in real time that a process is running within the process design space.
Streefland
M
M
Unit Research and Development, Netherlands Vaccine Institute, 3720 AL Bilthoven, The Netherlands. mathieu.streefland@nvi-vaccin.nl
Van Herpen
P F G
PF
Van de Waterbeemd
B
B
Van der Pol
L A
LA
Beuvery
E C
EC
Tramper
J
J
Martens
D E
DE
Toft
M
M
D001428:Bacterial Vaccines / Q000592:standards*; D001886:Bordetella pertussis / Q000254:growth & development*; D017277:Drug Approval; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000592:standards*
D001428:Bacterial Vaccines